ADCs or: How I Learned to Stop Worrying and Love Chemotherapy

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Antibody-drug conjugates (ADCs) represent a significant advancement in targeted cancer therapy.
• The efficacy of ADCs is heavily influenced by the characteristics of their cytotoxic payloads and the stability of their linkers.

Discussion:

• Weng and colleagues' work highlights the critical role of payload and linker chemistry in ADC development.
• Optimizing these components can enhance drug delivery and overcome mechanisms of chemoresistance.

Key Insights:

• Payload characteristics are emerging as key determinants of clinical activity in antibody-drug conjugates.
• Innovations in linker and payload chemistry are essential for the next evolutionary step in ADC therapeutics.

Outlook:

• Further research into ADC chemistry holds the potential to improve treatment outcomes for cancer patients.
• The development of novel linker and payload strategies may lead to more effective and less toxic cancer therapies.